Skip to main content
  • FDA Grants Medcura's LifeGel™ Coveted Breakthrough Device Designation Status

    LifeGel™ is the first and only hemostatic agent to receive Breakthrough Device Designation seeking a new and highly differentiated indication: in surgical procedures.

    Read more.
  • Medical Device Technology Pitch Competition

    Eight teams received funding and support to advance their medical device technologies.

    Read more.
  • GEn1E Lifesciences Adds NextGen Selective Immunomodulator Target to Portfolio, Broadens Pipeline

    GEn1E plans to use the novel discovery, which is licensed from University of Maryland, Baltimore, to develop therapies for pulmonary, oncology and muscle degenerative diseases.

    Read more.
  • CoapTech Study Demonstrates Patient Care and Hospital Cost Benefits of PUMA-G System

    The peer-reviewed study was conducted at the University of Maryland Baltimore Washington Medical Center. It confirms and quantifies cost and length of stay reductions with use of the PUMA-G System.

    Read more
  • UM Research Is Top 10 For NSF Higher Education R&D

    With $1.1 billion in combined research expenditures, the Baltimore/College Park enterprise placed 16th overall nationally and 10th among all public institutions in Research & Development (R&D) spending.

    Read more
  • Take a look inside the lifecycle of biotech startup Isoprene

    The UMB startup is working from the New Ventures lab in the BioPark.

    Read more
  • Isoprene Pharmaceuticals awarded a two-year $2 million SBIR Direct-to-Phase II grant

    The UMB startup is developing oral therapeutics for triple negative breast cancer and other cancers.


    Read more
  • Empower Therapeutics developing a simple, reliable brainwave biomarker for pain sensitivity

    The newly launched UMB startup has licensed technology developed by scientists at UMB and the University of Birmingham, U.K.

    Read more

Spotlight on...

UM Ventures has launched a series of initiatives for the Center for Maryland Advanced Ventures, including:

NEW ACCELERATOR: Trajectory Next
Trajectory Next is a 12-week post-accelerator program for digital health, bio-health, and life sciences startups.

The Baltimore Fund
The Baltimore Fund provides financial incentives to companies affiliated with Maryland Public Higher Education Institutions to locate in a network of innovation centers in Baltimore City.

The UMCP Fischell Institute
The UMCP Fischell Institute for Biomedical Devices is opening a satellite location at UMB to accelerate the development of innovative medical devices.

Maryland Momentum Fund
The University System of Maryland created the Maryland Momentum Fund, a $25 million early-stage investment program investing in USM-affiliated companies. The Maryland Momentum Fund is staffed by UM Ventures.

University of Maryland, Baltimore Institute for Clinical and Translational Research
The University of Maryland, Baltimore Institute for Clinical and Translational Research (ICTR) is pleased to announce the first round of UMB ICTR Accelerated Translational Incubator Pilot (ATIP) Grant funding opportunities for 2018-2019.


University of Maryland, College Park
University of Maryland, Baltimore

UM Ventures is a joint initiative of the University of Maryland, Baltimore and University of Maryland, College Park to commercialize technologies and expand industry collaboration.

Learn More